Rabeprazole



Rabeprazole
Systematic (IUPAC) name
2-[(4-(3-methoxypropoxy)- 3-methyl-pyridin-2-yl) methylsulfinyl]- 1H-benzoimidazole
Identifiers
CAS number 117976-89-3
ATC code A02BC04
PubChem 5029
DrugBank APRD01212
Chemical data
S 
Mol. mass 359.444 g/mol
Pharmacokinetic data
Bioavailability 52%
Metabolism Hepatic
Half life 1 - 1.5 hours
Excretion Renal
Therapeutic considerations
Licence data

US

Pregnancy cat.

B(US)

Legal status

℞-only(US)

Routes Oral

Rabeprazole is an antiulcer drug in the class of Janssen-Cilag as rabeprazole sodium under the brand names Aciphex and Pariet.

Pharmacology

Rabeprazole is a antibiotics. Rabeprazole has been demonstrated to be effective in patients with pathological hypersecretory activity (incl. Zollinger-Ellison Syndrome).

Indications and usage

  • gastric ulcer
  • peptic ulcer (PUD)
  • Maintenance of Healing of Erosive or Ulcerative GERD
  • Healing of Erosive and Ulcerative GERD
  • Healing of Duodenal Ulcers.
  • Treatment of Symptomatic GERD
  • Treatment of Pathological Hypersecretory conditions (Zollinger-Ellison)
  • Helicobactor Pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence

    Contraindications

  • hypersensitivity to Rabeprazole, substituted benzimidazoles or any of components of its pharmaceutical forms.
  • pregnancy
  • lactation

    Restriction of usage

  • acute hepatic failure
  • pediatric use in patients under 18 years of age (there are insufficient data about safety and efficiency of Rabeprazole in this group of patients)

    Side effects

    Rabeprazole Adverse reactions/Side effects include:

  • In clincal trials the most common side effect assessed as possibly or probably related to ACIPHEX was Headache in 2.4% of patients vs 1.6% taking placebo.
  • diarrhea
  • vomiting
  • nausea
  • abdominal pains
  • constipation
  • meteorism
  • dry mouth
  • increased or decreased appetite
  • asthenia
  • headache
  • sleeplessness
  • vertigo
  • thrombocytopenia
  • granulocytopenia
  • leukocytopenia
  • skin eruption
  • erythema
  • myalgia
  • arthralgia
  • muscle or bone pain

    Drug interactions

    Rabeprazole decreases the concentration of ketoconazole in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antiacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).

    Overdosage

    There is no available data on symptoms of rabeprazole overdose.

    How supplied

    Rabeprazole as Aciphex,Rabeloc, Pariet is supplied in:

  • Tablet, Enteric-Coated; 10mg
  • Tablet, Enteric-Coated; 20mg

    References

    • Morii M, Takata H, Fujisaki H, Takeguchi N., The potency of substituted benzimidazoles such as E3810, omeprazole, Ro 18-5364 to inhibit gastric H+, K(+)-ATPase is correlatedwith the rate of acid-activation of the inhibitor, Biochem. Pharmacol. 1990 Feb 15;39(4):661-7.
    • Prakash A, Faulds D., Rabeprazole, Drugs. 1998 Feb;55(2):261-7; discussion 268.
    •  
    This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Rabeprazole". A list of authors is available in Wikipedia.